James B Maurice1, Amee Patel, Alasdair J Scott, Krish Patel, Mark Thursz, Maud Lemoine. 1. aDepartment of Hepatology, St Mary's Hospital, Imperial College London bGKT School of Medicine, King's College London cDepartment of Surgery, St Mary's Hospital, Imperial College London dBarts and the London School of Medicine and Dentistry, Queen Mary University, London, UK.
Abstract
OBJECTIVE: To identify the prevalence and risk factors of nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH) and fibrosis in HIV-monoinfected patients. DESIGN: Systematic review and meta-analysis. METHODS: We searched Medline and Embase and included studies that enrolled HIV-monoinfected patients with NAFLD defined by imaging and/or liver histology. Data on prevalence and risk factors for NAFLD, NASH and fibrosis were collected for meta-analysis using random effects models. RESULTS: Ten studies were included from the United States of America (n = 4), Canada (n = 1), France (n = 2), Italy (n = 1), Japan (n = 1) and China (n = 1). The prevalence of NAFLD (Imaging studies), NASH and fibrosis (biopsied populations) were 35% [95% confidence interval (CI) 29-42], 42% (95% CI 22-64) and 22% (95% CI 13-34), respectively. Meta-analysis of risk factors showed that high BMI, waist circumference, type 2 diabetes, hypertension, triglycerides and high CD4 cell count were associated with NAFLD, whereas HIV viral load, duration of HIV infection, duration of antiretroviral therapy and CD4 cell count nadir were not. Patients with high BMI [mean difference (MD) 1.38, 95% CI 0.04-2.71 P = 0.04], fasting glucose (MD 0.80, 95% CI 0.47-1.13 P < 0.00001) and AST level (MD 13.00, 95% CI 4.34-21.65 P = 0.003) were at increased risk of significant liver fibrosis. CONCLUSION: NAFLD is frequently observed in HIV-monoinfected patients, and NASH is a common cause of unexplained abnormal liver function in patients selected for liver biopsy. Metabolic disorders are key risk factors independently of HIV parameters. Future trials on pharmacological interventions in NASH with fibrosis should include patients with HIV.
OBJECTIVE: To identify the prevalence and risk factors of nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH) and fibrosis in HIV-monoinfectedpatients. DESIGN: Systematic review and meta-analysis. METHODS: We searched Medline and Embase and included studies that enrolled HIV-monoinfectedpatients with NAFLD defined by imaging and/or liver histology. Data on prevalence and risk factors for NAFLD, NASH and fibrosis were collected for meta-analysis using random effects models. RESULTS: Ten studies were included from the United States of America (n = 4), Canada (n = 1), France (n = 2), Italy (n = 1), Japan (n = 1) and China (n = 1). The prevalence of NAFLD (Imaging studies), NASH and fibrosis (biopsied populations) were 35% [95% confidence interval (CI) 29-42], 42% (95% CI 22-64) and 22% (95% CI 13-34), respectively. Meta-analysis of risk factors showed that high BMI, waist circumference, type 2 diabetes, hypertension, triglycerides and high CD4 cell count were associated with NAFLD, whereas HIV viral load, duration of HIV infection, duration of antiretroviral therapy and CD4 cell count nadir were not. Patients with high BMI [mean difference (MD) 1.38, 95% CI 0.04-2.71 P = 0.04], fasting glucose (MD 0.80, 95% CI 0.47-1.13 P < 0.00001) and AST level (MD 13.00, 95% CI 4.34-21.65 P = 0.003) were at increased risk of significant liver fibrosis. CONCLUSION: NAFLD is frequently observed in HIV-monoinfectedpatients, and NASH is a common cause of unexplained abnormal liver function in patients selected for liver biopsy. Metabolic disorders are key risk factors independently of HIV parameters. Future trials on pharmacological interventions in NASH with fibrosis should include patients with HIV.
Authors: Takara L Stanley; Lindsay T Fourman; Meghan N Feldpausch; Julia Purdy; Isabel Zheng; Chelsea S Pan; Julia Aepfelbacher; Colleen Buckless; Andrew Tsao; Anela Kellogg; Karen Branch; Hang Lee; Chia-Ying Liu; Kathleen E Corey; Raymond T Chung; Martin Torriani; David E Kleiner; Colleen M Hadigan; Steven K Grinspoon Journal: Lancet HIV Date: 2019-10-11 Impact factor: 12.767
Authors: Veeral H Ajmera; Edward Cachay; Christian Ramers; Irine Vodkin; Shirin Bassirian; Seema Singh; Neeraj Mangla; Richele Bettencourt; Jeannette L Aldous; Daniel Park; Daniel Lee; Jennifer Blanchard; Adrija Mamidipalli; Andrew Boehringer; Saima Aslam; Olof Dahlqvist Leinhard; Lisa Richards; Claude Sirlin; Rohit Loomba Journal: Hepatology Date: 2019-06-18 Impact factor: 17.425
Authors: Lauren E Mellor-Crummey; Jordan E Lake; Holly Wilhalme; Chi-Hong Tseng; Philip M Grant; Kristine M Erlandson; Jennifer C Price; Frank J Palella; Larry A Kingsley; Matthew Budoff; Wendy S Post; Todd T Brown Journal: J Clin Gastroenterol Hepatol Date: 2018-07-30
Authors: James B Maurice; Robert Goldin; Andrew Hall; Jennifer C Price; Giada Sebastiani; Caryn G Morse; Laura Iogna Prat; Hugo Perazzo; Lucy Garvey; Patrick Ingiliz; Giovanni Guaraldi; Emmanouil Tsochatzis; Maud Lemoine Journal: Clin Infect Dis Date: 2021-10-05 Impact factor: 9.079
Authors: Lindsay T Fourman; Takara L Stanley; Isabel Zheng; Chelsea S Pan; Meghan N Feldpausch; Julia Purdy; Julia Aepfelbacher; Colleen Buckless; Andrew Tsao; Kathleen E Corey; Raymond T Chung; Martin Torriani; David E Kleiner; Colleen M Hadigan; Steven K Grinspoon Journal: Clin Infect Dis Date: 2021-06-15 Impact factor: 9.079
Authors: Suman Srinivasa; Kathleen V Fitch; Nabiha Quadri; Patrick Maehler; Timothy K O'Malley; Edgar L Martinez-Salazar; Tricia H Burdo; Meghan Feldpausch; Martin Torriani; Gail K Adler; Steven K Grinspoon Journal: J Endocr Soc Date: 2018-09-03